Catyalyst Pharma (CPRX) Announces Publication of CPP-115 Data in EBCR Journal
- World stocks get the jitters as U.S. presidential debate looms
- LANXESS to Acquire Chemtura (CHMT) in ~$2.5B Deal
- Yen gains after Kuroda sticks to negative rate script
- Oil steady as market awaits Algiers meeting; funds cut bullish bets
- Clinton and Trump to square off in highly anticipated debate showdown
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that the journal of Epilepsy & Behavior Case Reports has accepted for publication a case report on the efficacy of CPP-115 in a child with refractory infantile spasms.
The case report presents a child treated with CPP-115 through an investigational new drug protocol who experienced a significant reduction of seizures with no evidence of retinal dysfunction. The research paper made the following conclusions:
- The case study suggests sustained efficacy and tolerability of CPP-115 in treating epileptic spasms
- It reported reduction in seizure frequency and documented improvements in the EEG interictal and ictal record temporally associated with CPP-115 initiation for this patient
- It reported that in the context of refractory infantile spasms and associated morbidity, mortality, and poor neurodevelopmental outcomes, CPP-115 is potentially a promising alternative to vigabatrin therapy
Prior to treatment with CPP-115, the patient had failed ten drugs and the ketogenic diet, and had approximately 100 seizures per day. One year after starting CPP-115 and coming off of clobazam and vigabatrin, the patient’s reported seizures have seen a marked reduction in frequency and his cognition and behavior have improved.
“There is a significant unmet medical need in the area of refractory infantile spasms, as parents of children who have infantile spasms have a very difficult choice when it comes to treatment options, weighing both drug-related risks and adequate treatment,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “Our pediatric epilepsy experts advise us that approximately half of the children diagnosed with infantile spasms are refractory to the medications approved for the treatment of infantile spasms.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TerraForm Power (TERP) Files Initial Proof of Claim in SunEdison's Chapter 11 Bankruptcy
- Magna Int'l (MGA) to Acquire BÖCO Group of Companies
- Exelixis (EXEL) Announces Initiation of CS-3150 Phase 3 as Selective Mineralocorticoid Receptor Antagonist
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!